Pfizer, Inc. · NYSE:PFE
Pfizer — 43rd Annual J.P. Morgan Healthcare Conference 2025
11 slides from Pfizer's conference presentation, Jan 13, 2025
Slide 1: Pfizer Investor Overview At 2025 J.P. Morgan Healthcare Conference
Pfizer Investor Overview At 2025 J.P. Morgan Healthcare Conference January 2025 1
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information • These materials will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We include forward-
Slide 3: 2025 Key Priorities: Enhancing Shareholder Value
2025 Key Priorities: Enhancing Shareholder Value • Improve R&D productivity with sharpened focus • Expand margins and maximize operational efficiency • Achieve commercial excellence in our key categories • Optimize capital allocation 3
Slide 4: 2025 Financial Guidance
2025 Financial Guidance1 Reported Revenues $61.0 to $64.0 Billion Adjusted1 SI&A Expenses $13.3 to $14.3 Billion Adjusted1 R&D Expenses $10.7 to $11.7 Billion Effective Tax Rate on Adjusted1 Income ~15.0% Adjusted1 Diluted EPS $2.80 to $3.00 1. See slide 11 for definitions, including with respect to
Slide 5: Inflation Reduction Act (IRA) Impact in 2025
Inflation Reduction Act (IRA) Impact in 2025 2025 IRA Part D Redesign Items Impacting Our Business • $2,000 annual out-of-pocket cap and new Prescription Payment Plan • Sunsetting of the Coverage Gap Discount Program and addition of new manufacturer discounts in the initial and catastrophic coverage
Slide 6: 2025 Key Product Assumptions and Considerations
2025 Key Product Assumptions and Considerations Comirnaty*: Materially stable vaccination rates and market share in U.S. and revenue phasing similar to 2024, primarily concentrated in the back-half of the year with the distribution between Q3 and Q4 dependent on the timing of strain selection and ap
Slide 7: Select 2025 Pipeline Catalysts
Select 2025 Pipeline Catalysts Anticipated Regulatory Decisions Anticipated Phase 3 Readouts Potential Pivotal Program Starts Compound Indication Compound Indication Compound Indication BRAFTOVI 1H 2025 RSV Infection 1L BRAFm mCRC ABRYSVO (EU) (18-59 Years) (BREAKWATER PFS) Atirmociclib (CDK4i) 1L m
Slide 8: Key Takeaways
Key Takeaways • Confident we will deliver on 2025 financial guidance • Intense pipeline focus to deliver improved R&D productivity • Modest margin improvement in 2025 • Strong defense of core products, improvement of market share in key categories • Maintain growing dividend, meet de-levering target
Slide 9: Glossary: Select Pipeline Assets (1 of 2)
Glossary: Select Pipeline Assets (1 of 2) Phase of Compound Name Mechanism of Action Target Indication Development Submission Type ADCETRIS® (brentuximab CD30-directed antibody-drug conjugate Diffuse Large B-Cell Lymphoma (DLBCL) (Biologic)† Registration Product Enhancement vedotin) Combo w/ XTANDI®
Slide 10: Glossary: Select Pipeline Assets (2 of 2)
Glossary: Select Pipeline Assets (2 of 2) Phase of Compound Name Mechanism of Action Target Indication Development Submission Type PF-07831694 Prophylactic vaccine – protein subunit Clostridioides difficile (C. difficile) – updated formulation Phase 2 New Molecular Entity PF-07872412 Prophylactic va
Slide 11: Footnotes
Footnotes (1) Pfizer does not provide guidance for U.S. generally accepted accounting principles (GAAP) Reported financial measures (other than revenues) or a reconciliation of forward- looking non-GAAP financial measures to the most directly comparable GAAP Reported financial measures on a forward-
Pfizer — 43rd Annual J.P. Morgan Healthcare Conference 2025 on 6ix